← Back to Search

Antiepileptic

Levetiracetam for Alzheimer's Disease (LAPSE Trial)

Phase 2
Waitlist Available
Led By Timothy R Malone, MD
Research Sponsored by Walter Reed National Military Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must not have
History of encephalitis/meningitis
Previous Epilepsy diagnosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at enrollment, week 7, week 15, week 27, and month 12
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial will study whether or not treating seizures can improve neuro-psychiatric symptoms in Alzheimer's patients.

Who is the study for?
This trial is for people with Alzheimer's who show signs of agitation or depression (neuro-psychiatric symptoms) and have had a recent brain scan without seizure indicators. They must score below 26 on the MMSE, indicating cognitive impairment, and be on stable medication doses. A reliable caregiver is required to help them throughout the study.
What is being tested?
The LAPSE trial tests if Levetiracetam can reduce neuro-psychiatric symptoms in Alzheimer's patients with seizure-like activity. Participants will take this drug for a year while their symptoms, cognition, quality of life, and disease severity are monitored.
What are the potential side effects?
Levetiracetam may cause side effects such as drowsiness, weakness, infection risk increase due to lowered blood cell counts, loss of appetite or digestive issues like nausea or vomiting; mood changes including anxiety or depression; skin reactions; and other potential nervous system effects.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had encephalitis or meningitis in the past.
Select...
I have been diagnosed with epilepsy.
Select...
I had major depression or behavioral issues before my Alzheimer's diagnosis.
Select...
I have had a head injury that made me unconscious for over 30 minutes.
Select...
I am not pregnant, breastfeeding, nor planning to become pregnant during the trial.
Select...
I have a history of Korsakoff's syndrome.
Select...
I have surgery planned that will need general anesthesia during the trial.
Select...
My cancer needs chemotherapy now.
Select...
I do not have conditions like severe kidney, liver issues, or untreated vitamin deficiencies that could explain my memory problems.
Select...
My scans show possible reasons for seizures or memory loss.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at enrollment, week 7, week 15, week 27, and month 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at enrollment, week 7, week 15, week 27, and month 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Neuropsychiatric Inventory Score (NPI)
Secondary study objectives
Change in Alzheimer's Disease Cooperative study - Clinical Global Impression of Change (ADCS-CGIC)
Change in Clinical Dementia Rating Sum of Boxes (CDR-SOB)
Change in EuroQol 5-Dimension (EQ-5D)
+1 more

Side effects data

From 2006 Phase 4 trial • 251 Patients • NCT00160654
30%
Somnolence
14%
Dizziness
6%
Nausea
6%
Fatigue
6%
Headache
6%
Sedation
2%
Convulsion
1%
Grand mal convulsion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Levetiracetam

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: LevetiracetamExperimental Treatment1 Intervention
All patients with epileptiform activity on initial screening EEG will receive levetiracetam for 1 year
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Levetiracetam
FDA approved

Find a Location

Who is running the clinical trial?

Walter Reed National Military Medical CenterLead Sponsor
140 Previous Clinical Trials
33,108 Total Patients Enrolled
Timothy R Malone, MDPrincipal InvestigatorWalter Reed National Military Medical Center

Media Library

Levetiracetam (Antiepileptic) Clinical Trial Eligibility Overview. Trial Name: NCT04004702 — Phase 2
Alzheimer's Disease Research Study Groups: Levetiracetam
Alzheimer's Disease Clinical Trial 2023: Levetiracetam Highlights & Side Effects. Trial Name: NCT04004702 — Phase 2
Levetiracetam (Antiepileptic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04004702 — Phase 2
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top